The efficacy and safety of dual blockage of the renin-angiotensin-aldosterone system in patients with type 2 diabetes, hypertension and obesity without renal dysfunction

The purpose of the study was to evaluate the clinical efficacy and safety of dual RAAS blockage during treatment with angiotensin-converting enzyme (ACE) inhibitors in combination with a direct renin inhibitor (PIR) aliskiren versus combination therapy with ACE inhibitors and angiotensin receptor blocker II (ARB) valsartan in patients with type 2 diabetes mellitus (T2DM), arterial hypertension (AH) and obesity, without renal dysfunction. Materials and methods. The study included 26 patients with T2DM (10 men and 16 women, mean age 59,0±6,2 years) with inadequate control of blood pressure (over 130 and/or 80 mm Hg) on prior antihypertensive therapy and without renal dysfunctions (glomerular filtration rate (GFR)> 60 ml/min/1, 73 m2 and the of albumin/creatinine (A/C) ratio in the morning urine sample <10 mg/mol). After screening with the continuation of the initial therapy, including ACE inhibitors, 14 patients were added aliskiren 150–300 mg/day, 12 patients – valsartan 80–160 mg/day. Evaluation of the treatment effectiveness in terms of blood pressure (mean of three consecutive measurements in the sitting position) and the parameters of renal function (serum creatinine and potassium, GFR, A/C ratio in the urine) was performed at 4, 12 and 24 weeks of therapy. Results. In the group of patients treated with aliskiren, after 4 weeks of treatment a significant decrease in systolic and diastolic blood pressure (SBP and DBP, respectively) was noted as compared to baseline: 146,1 and 138,9 mm Hg, p<0,05, 87,1 and 81,1 mm Hg, p <0,05, respectively; with systolic BP after 24 weeks of treatment decreased to 127,8 (-18,2 mm Hg), p<0,05, diastolic BP to 75,0 (-12, 1 mm Hg), p<0,05, the target blood pressure (≤130/80 mm Hg) was achieved in 83% of patients. The group of patients treated with valsartan, after 4 weeks of therapy showed a significant reduction in systolic BP 148 and 141,6 mm Hg, p <0,05, diastolic BP - to 85,8 and 81,7 mm Hg, p=0,059; after 24 weeks systolic BP decreased to 128,7 (-19,3 mm Hg), p=0,05, diastolic BP – to 77,5 (-8,3 mm Hg), p=0,07, the target blood pressure was achieved in 78% of patients. When monitoring the safety of therapy in terms of potassium, serum creatinine, GFR, and A/C urine ratio statistically significant differences between the groups at 4, 12, 24 weeks of treatment were observed. Conclusion. Results of the study demonstrate the efficacy and safety of dual RAAS blockage in patients with T2DM and obesity with no prior renal impairment.

Type 2 diabetes mellitus, hypertension, dual RAAS blockage

1. National PBM Bulletin – Pharmacy Benefits Management Services. www.pbm.va.gov/../Aliskiren%20ADEs%20In%20Combination%20ACEI%20or%20ARB

2. Direct Healthcare Professional Communication on potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes and renal impairment and/or cardiovascular disease treated with aliskiren (Tekturna®) tablets and aliskiren-containing combination products. January 2012. Novartis Pharmaceuticals Corporation; East Hanover NJ. http://www.pharma.us.novartis.com/assets/pdf/TKT-1118923%20Dear_HCP_Letter_email_with%20Tek-Val%20PIs_vf.pdf.

3. Архипов М.В., Арутюнов Г.П., Бойцов С.А., Галявич А.С., Карпов Ю.А., Кобалава Ж.Д., Маколкин В.И., Мартынов А.И., Небиеридзе Д.В., Недогода С.В., Остроумова О.Д., Ощепкова Е.В., Смоленская О.Г., Шальнова С.А., Чазова И.Е. Новые Российские рекомендации по АГ – приоритет комбинированной терапии Российское медицинское общество по артериальной гипертонии. Секция доказательной гипертензиологии. Информационное письмо. Системные гипертензии 2011;3:58–61.

4. Шамхалова М.Ш., Трубицына Н.П., Шестакова М.В., Гончаров Н.П., Кацая Г.В. Феномен частичного ускользания блокады ангиотензина II у больных СД 2 типа и диабетической нефропатией. Нефрология и диализ 2007;3(9):348.

5. Brown M.J. Aliskiren. Circulation 2008;118:773–784.

6. Trimarchi Н. Role of aliskiren in blood pressure control and renoprotection. Int. J. Nephrol. Renovasc. Dis. 2011;4:41–48.

7. Fogari R., Zoppi A.New class of agents for treatment of hypertension: focus on direct renin inhibition, Vasc Health Risk Manag 2010;6:869–882.

8. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med 2006;23(5): 469–480.

9. Uresin Y., Taylor A.A., Kilo C., Tschöpe D., Santonastaso M., Ibram G., Fang H., Satlin A. Efficacy and safety of the direct rennin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin Angiotensin Aldosterone Syst 2007;8(4):190–200.

10. Качнов В.А., Кольцов А.В., Тыренко В.В., Никитин А.Э., Синопальников Д.О., Щербатюк О.В., Мешкова М.Е., Ветушко В.Д. Влияние комбинированной блокады ренин-ангиотензин-альдостероновой системы с применением Расилеза и эналаприла на уровень микроальбуминурии у больных гипертонической болезнью. Системные гипертензии 2010;4:38–41.

11. Oparil S., Yarows SA, Patel S., Fang H., Zhang J., Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370(9583):221–9.

12. Drummond W., Sirenko Y.M., Ramos E., Baek I., Keefe D.L. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study. Am J Cardiovasc Drugs 2011;11(5):327–33.

13. Susic D., Lippton H., Knight M., Frohlich E. Cardiovascular effects of nonproteolytic activation of prorenin. Hypertension 2006;48(6):113–114.

14. Nguyen G., Delarue F., Burckle C., Bouzhir L., Giller T., Sraer J. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest 2002;109:1417–1427.

15. Persson F., Rossing P., Reinhard H., Guhl T., Stehouwer CD, Schalkwijk C. Renoprotective effects of direct renin inhibition compared to and in combination with maximum recommended dose of irbesartan in patients with type 2 diabetes and albuminuria. Kidney Int 2008;73:1419–25.

16. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433–46.

17. Parving H.H., Brenner B., McMurray J.J.V., de Zeeuw D., Haffner S.M., Solomon S.D., Chaturvedi N., Ghadanfar M. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24(5):1663–71.

18. Aliskiren adverse events in combination with an angiotensin-converting enzyme inhibitor or angiotensin II receptor antagonist in patients with type II diabetes mellitus. National PBM Bulletin, January 13, 2012 (http://www.pbm.va.gov/vamedsafe/Aliskiren).

19. Haynes R., Mason Р., Rahimi К., Landray М.J. Dual blockade of the renin–angiotensin system: are two better than one? Nephrology Dialysis Transplantation 2009;24(12):3602–3607.

20. Mogensen S.E., Neldam S., Tikkanen I., Oren S., Viskoper R., Watts R.W., Cooper M.E. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000 December 9;321(7274):1440–1444.

21. Mann JF, Schmieder RE, McQueen M., Dyal L., Schumacher H., Pogue J., Wang X. Renal outcomes with telmisartan, ramipril or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008; 372(9638):547–53.